All In Biotech

Drug Trial Radar · NCT06868082

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and Non-Japanese Participants

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jun 20, 2025

Primary completion

Feb 2, 2026

Study completion Feb 2, 2026

Sponsor

Lead sponsor
Uniquity One (UNI)Industry
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants

Conditions

  • Healthy

Interventions

  • SolrikitugBiological

    Solrikitug Formulation 1

  • SolrikitugBiological

    Solrikitug Formulation 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 165 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.